Hints and tips:
Related Special Reports
...The amount raised by private equity funds globally last year fell to a six-year low, according to S&P Global....
...BMS’s shares have fallen roughly 25 per cent this year, underperforming the wider healthcare sector in a year when the S&P 500 has risen nearly 25 per cent....
...High-grade pharma group Bristol Myers Squibb sold $13bn of debt on Wednesday....
...It’s a catchy name that looks good in headlines and investor presentations, and it’s backed up by the kind of gains that make European investors sick with envy (even if we’re all supposed to be worried about...
...Its investors, however, may find the group’s latest proposition does not fit them so well....
...UK’s AstraZeneca, German software company SAP and French healthcare firm Sanofi....
...Novo Nordisk has a similar effect on healthcare: Here is the tricky bit, though....
...Eye-watering valuations have become a turn-off for investors and have knocked 5 per cent off the US S&P 500 index over the past month....
...This has been a perfect theme for investors for almost a year. Catchy nickname? Check. Eye-popping numbers? Check. Gigantic returns for investors who got in before the latest sweep higher? Sure....
...First, we need more ways for private investors to deploy capital alongside government funds....
...The benchmark S&P 500 was up 0.1 per cent in early trading New York on Monday, the first day of the second quarter. The tech-dominated Nasdaq Composite was up 0.5 per cent....
...A better look for the UK is GSK in a head-to-head with Bristol-Myers: This time, the UK company has stronger prospective earnings growth, due to Bristol’s patent expirations, as well as stronger returns...
...The investor group also includes private credit groups Ares Management and HPS, and L Catterton, a private equity group that invested in Equinox in 2017....
...In contrast, the S&P 500’s price-to-book ratio is close to the record 5 times it touched in 2021 and 2000 (the Nasdaq’s P/B ratio is close to 7.5 times)....
...Since 1990, missing the 30 best days of the S&P 500 cuts your compound returns in half....
...This would encourage the US government and private insurers to include the treatment in its healthcare coverage....
...The company’s Ageing Population and Healthcare Innovation ETFs have also fallen out of favour, alongside the L&G Cyber Security Ucits ETF....
...Free cash flow, however, reconciles those book accounting accruals of the P&L ledger to capture the real flows of actual dollars coming in and out....
...Communications Q1 Tuesday Bank of England chief economist Huw Pill speaks at the London campus of the University of Chicago, Booth School of Business EU, France, Germany, India, Italy, Japan, UK, US: S&P...
...Wall Street’s benchmark S&P 500 gained 0.3 per cent shortly after the opening bell, with healthcare and consumer cyclicals among the best-performing stocks....
...A separate report released on Tuesday by S&P Global Ratings painted a similar picture, with global defaults jumping by four-fifths last year to 153....
...Large drugmakers have also underperformed, with the S&P 500 pharmaceutical sub-index heading for its worst performance relative to the broader S&P 500 in at least 20 years....
...“There’s been a noticeable, dramatic improvement in sentiment among investors,” said Rahul Chaudhary, head of healthcare equity capital markets at Leerink Partners....
...Investors are buying up European travel, retail and luxury goods shares, betting that a rebound in the region’s economy will tempt consumers to spend on more on holidays and expensive items....
...Foreign investors fear that America could extend sanctions against Chinese digital technology to its pharmaceuticals. This would hurt science and healthcare. But there is no cure for human folly....
International Edition